Compare · NVO vs SPRY
NVO vs SPRY
Side-by-side comparison of Novo Nordisk A/S (NVO) and ARS Pharmaceuticals Inc. (SPRY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and SPRY operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $191.15B, about 207.9x SPRY ($919.5M).
- Over the past year, NVO is down 44.1% and SPRY is down 33.1% - SPRY leads by 11.0 points.
- NVO has been more active in the news (8 items in the past 4 weeks vs 2 for SPRY).
- NVO has more recent analyst coverage (25 ratings vs 13 for SPRY).
- Company
- Novo Nordisk A/S
- ARS Pharmaceuticals Inc.
- Price
- $43.97+2.76%
- $9.59+3.68%
- Market cap
- $191.15B
- $919.5M
- 1M return
- -6.43%
- +11.12%
- 1Y return
- -44.15%
- -33.15%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2020
- News (4w)
- 8
- 2
- Recent ratings
- 25
- 13
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care
Latest SPRY
- Drew Brees Collaborates with ARS Pharmaceuticals to Raise Awareness About Living Life with Severe Allergies
- SEC Form 3 filed by new insider Casale Donn
- SEC Form 10-Q filed by ARS Pharmaceuticals Inc.
- ARS Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- ARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Update
- SEC Form 8-K filed by ARS Pharmaceuticals Inc.
- ARS Pharmaceuticals Strengthens Leadership Team with Appointment of Industry Veteran Donn Casale as President
- ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2026 Financial Results
- SEC Form DEFA14A filed by ARS Pharmaceuticals Inc.
- SEC Form DEF 14A filed by ARS Pharmaceuticals Inc.